Saba could extinguish Baillie Gifford US Growth Trust if shareholders do not vote against it at an upcoming AGM ...

Analysts expect rising rates to weigh on an already expensive equity market and even trigger a short-term sell-off. Goldman Sachs analyst Ben Snider said Fed tightening is “one of the dynamics that ...

Régis Schultz, chief executive of JD Sports Fashion (JD.), blamed “cost of living pressures, footwear product cycle headwinds and a highly promotional market” for the sportswear retailer’s falling ...

Midwich saw a working capital outflow of £23.9mn during the period – a partial consequence of seasonality of demand, ...

OXB (OXB), formerly Oxford BioMedica, enjoyed a steady first half after the contract medicines manufacturer reported a 9 per ...

In recent years, this momentum style has been dominant and earlier this summer, famed stock picker and Fundsmith founder ...

Although some demand remains lumpy, recurring revenues are starting to dominate this logistics supplier’s top line ...

That, along with other one-off costs from the restructuring, meant M&C swung to a £161,000 pre-tax loss in the first half. Margins were already squeezed by spending to scale up businesses including ...

Target Healthcare Reit (THRL) likes to position itself as “stable and boring”, in the words of lead fund manager Kenneth MacKenzie, chief executive of Target’s investment manager.

PureTech will fund a slice of the trials via its equity stake, rather than direct spend, while retaining a long-term royalty interest of 1–3 per cent. In other words, the development risks have been ...

As a result, the FTSE 100 is down 0.2 per cent this morning, and shares in Paris and Frankfurt have fallen 0.15 and 0.4 per ...

Healthcare diagnostics software platform Diaceutics (DXRX) appears to have hit an inflection point in its growth. Diaceutics’ DXRX data platform provides ‘clinical intent signals’ to drug ...